Dalton Smart
Chief Executive Officer at HARPOON THERAPEUTICS, INC.
Net worth: 555 891 $ as of 2024-05-30
Dalton Smart active positions
Companies | Position | Start | End |
---|---|---|---|
MERCK & CO., INC. | Comptroller/Controller/Auditor | 2023-12-03 | - |
Corporate Officer/Principal | 2023-08-31 | 2023-12-03 | |
HARPOON THERAPEUTICS, INC. | Chief Executive Officer | - | - |
ACCELERON PHARMA INC. | Director/Board Member | - | - |
President | - | - | |
Junior Achievement of New Jersey, Inc. | Director/Board Member | - | - |
Career history of Dalton Smart
Statistics
International
United States | 5 |
Operational
Director/Board Member | 2 |
Comptroller/Controller/Auditor | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
MERCK & CO., INC. | Health Technology |
Private companies | 3 |
---|---|
Junior Achievement of New Jersey, Inc. | |
Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
- Stock Market
- Insiders
- Dalton Smart
- Experience